Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Products, net	$ 231,495	$ 188,825
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Collaboration	$ 22,005	$ 22,005
Total revenues	253,500	210,830
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)	35,017	31,443
Research and development	245,679	194,250
Selling, general and administrative	110,714	71,840
Amortization of in-licensed rights	178	178
Total cost and expenses	391,588	297,711
Operating loss	(138,088)	(86,881)
Other loss, net:
Loss on debt extinguishment	(387,329)	0
Other income (expense), net	12,707	(17,265)
Total other (loss), net	(374,622)	(17,265)
Loss before income tax expense (benefit)	(512,710)	(104,146)
Income tax expense (benefit)	4,045	879
Net loss	(516,755)	(105,025)
Other comprehensive income (loss):
Unrealized gains (losses) on investments, net of tax	1,245	(286)
Total other comprehensive income (loss)	1,245	(286)
Comprehensive loss	$ (515,510)	$ (105,311)
Net loss per share - basic and diluted	$ (5.86)	$ (1.20)
Net loss per share - basic and diluted	$ (5.86)	$ (1.20)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share	88,186	87,253
Weighted average number of shares of common stock used in computing basic and diluted net loss per share	88,186	87,253